Sufentanil ( DrugBank: Sufentanil )
2 diseases
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
70 | 広範脊柱管狭窄症 | 1 |
280 | 巨大動静脈奇形(頚部顔面又は四肢病変) | 1 |
70. 広範脊柱管狭窄症
臨床試験数 : 96 / 薬物数 : 203 - (DrugBank : 60) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 89
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2019-003590-25-NL (EUCTR) | 15/06/2020 | 15/06/2020 | Epidural analgesia after back surgery | a Randomized controlled trial for epidural Analgesia for Pain relief after lumbar Interlaminar Decompressive spine surgery - RAPID - RAPID | Lumbar spinal stenosis MedDRA version: 21.0;Level: LLT;Classification code 10041595;Term: Spinal stenosis lumbar;System Organ Class: 100000004859;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | Trade Name: Bupivacaïne HCl 0,125% / Sufentanil 50 µg flacon à 50 ml Product Name: Bupivacaine Product Code: Sufentanil | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 34 | Phase 4 | Netherlands |
280. 巨大動静脈奇形(頚部顔面又は四肢病変)
臨床試験数 : 25 / 薬物数 : 29 - (DrugBank : 15) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 153
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02552459 (ClinicalTrials.gov) | September 2015 | 26/5/2015 | Effect of Dexmedetomidine Combined With Sufentanil for Postoperative Intravenous Analgesia in Neurosurgery | Effect of Dexmedetomidine Combined With Sufentanil for Postoperative Intravenous Analgesia in Neurosurgery: A Randomized Controlled Study | Arteriovenous Malformation | Drug: Sufentanil;Drug: dexmedetomidine 1;Drug: dexmedetomidine 2;Drug: dexmedetomidine 3 | First Affiliated Hospital, Sun Yat-Sen University | NULL | Recruiting | 18 Years | 65 Years | Both | 120 | Phase 4 | China |